Dileep Puppala, MD
Pulmonary Disease · Houston, TXNPI 1215989900
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $75,732 of the $107,536 with a category attached, or 70.4%. 55 manufacturers reported payments, led by GSK at 40.8% of the total. Reporting peaked in 2019 at $35,071 and has fallen 83.6% since, to $5,738 in 2025. Among pulmonary disease clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,140 payments — averaging $94.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$44K
- Sanofi$17K
- Mylan Specialty L.p.$15K
- Regeneron Healthcare Solutions, Inc.$9K
- AstraZeneca$7K
- Inspire Medical Systems, Inc.$4K
- plus $12K from 49 others
Across 270 payments — averaging $3676.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$446K
- Verona Pharma, Inc.$168K
- Insmed, Inc.$105K
- Chiesi USA, Inc.$84K
- AstraZeneca$62K
- Astrazeneca AB$40K
- plus $86K from 7 others
What the payments were for
- Consulting fees$7221%
- Speaking & faculty fees$75,73270%
- Travel & lodging$3,0423%
- Food & beverage$27,58326%
- Education$4570%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$22,908
- DUPIXENT$22,398
- NUCALA$14,885
- Yupelri$13,199
- FASENRA$3,994
- ANORO ELLIPTA$3,714
- Inspire$1,971
- Inspire Upper Airway Stimulation System$1,159
- UPTRAVI$368
- TEZSPIRE$344
- OPSUMIT$249
- BREZTRI$244
- CHARTIS CATHETER$146
- ZEPHYR DELIVERY CATHETER$146
- ZEPHYR ENDOBRONCHIAL VALVE$146
- PULMONX CHARTIS TABLET CONSOLE$146
- Esbriet$132
- AIRSUPRA$122
- Arikayce$121
- Renal - CRRT$118
How this compares
$107,536 in reported general payments places this provider in the 95th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prolastin CAlpha-1-Proteinase Inhibitor | 39 | $556,094 |
| OfevNintedanib Esylate | 38 | $495,898 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 541 | $418,949 |
| OpsumitMacitentan | 20 | $254,562 |
| NucalaMepolizumab | 28 | $213,744 |
| TezspireTezepelumab-Ekko | 27 | $110,548 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 100 | $66,881 |
| Spiriva RespimatTiotropium Bromide | 87 | $55,246 |
| Breo ElliptaFluticasone/Vilanterol | 90 | $46,041 |
| SymbicortBudesonide/Formoterol Fumarate | 93 | $31,889 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 38 | $29,098 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 234 | $28,565 |
| XareltoRivaroxaban | 26 | $19,349 |
| EliquisApixaban | 24 | $18,161 |
| Incruse ElliptaUmeclidinium Bromide | 46 | $17,422 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Incruse Ellipta, Anoro Ellipta | $43,853 | $718,663745 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $595 | $590,858179 claims |
| Grifols USA, LLCProlastin C | $324 | $556,09439 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $2,055 | $254,56220 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $7,271 | $209,318220 claims |
| Johnson & JohnsonXarelto | $338 | $19,34926 claims |
| PfizerEliquis | $125 | $18,16124 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in Houston
- Nicola HananiaHouston$1.3M
- Sandeep SahayHouston$378K
- Zeenat SafdarHouston$291K
- Howard HuangHouston$194K
- Brandy McKelvyHouston$168K
- Alexander StadnykHouston$158K
- Lisa KopasHouston$120K
- Sandeep GuptaHouston$118K
- Roberto CasalHouston$113K
- Phuongdung NguyenHouston$95K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.